On June 30, 2024, YNBY INTL announced its unaudited interim financial report, which showed a slight increase of 1.6% in revenue from its goods and commodity trading business, reaching approximately HKD 362,300,000. However, a decrease in gross margin and an increase in general and administrative expenses led to a decrease in net profit. During the reporting period, the basic and diluted earnings per share were 0.02 HK cents. As of June 30, 2024, the company had approximately HKD 179,300,000 in cash and cash equivalents and total assets of approximately HKD 345,300,000. The Board of Directors did not recommend an interim dividend. Shareholders' equity of the company slightly increased to approximately HKD 244,300,000. The company faces challenges including global economic conditions, downward pressure on China's trade business, and stable growth...Show More

On June 30, 2024, YNBY INTL announced its unaudited interim financial report, which showed a slight increase of 1.6% in revenue from its goods and commodity trading business, reaching approximately HKD 362,300,000. However, a decrease in gross margin and an increase in general and administrative expenses led to a decrease in net profit. During the reporting period, the basic and diluted earnings per share were 0.02 HK cents. As of June 30, 2024, the company had approximately HKD 179,300,000 in cash and cash equivalents and total assets of approximately HKD 345,300,000. The Board of Directors did not recommend an interim dividend. Shareholders' equity of the company slightly increased to approximately HKD 244,300,000. The company faces challenges including global economic conditions, downward pressure on China's trade business, and stable growth in China's cosmetic and health product market. The company will continue to drive growth in its goods and commodity trading business. The company's Board of Directors is diverse and has established a Nomination Committee, Remuneration Committee, and Audit Committee to oversee corporate governance. The company complied with corporate governance practices during the reporting period, although the Chairman of the Board of Directors was unable to attend the annual meeting. The company's share purchase plan expired in 2023, with no share purchase rights granted or exercised during the period.